Shukra Pharmaceuticals
40.97
+0.80(+1.99%)
Market Cap₹1,794.00 Cr
PE Ratio178.13
IndustryHealthcare
Company Performance:
1D+1.99%
1M+23.78%
6M+214.19%
1Y+503.39%
5Y+14,532.14%
View Company Insightsright
More news about Shukra Pharmaceuticals
05Sept 25
Shukra Pharmaceuticals Proposes 3:1 Bonus Issue and Capital Increase via Postal Ballot
Shukra Pharmaceuticals Limited has announced several corporate actions via postal ballot. The company proposes to increase its authorized share capital from Rs. 12.00 crore to Rs. 44.00 crore and issue bonus shares in a 3:1 ratio. Other proposals include amending the Articles of Association and revising the Managing Director's remuneration to Rs. 8.00 lakh monthly. E-voting for these resolutions will be held from March 5 to April 3, 2024, with March 1, 2024, set as the record date for the bonus issue. The company's current paid-up capital is Rs. 10.95 crore.
28Aug 25
Shukra Pharma Secures ₹24.06 Crore Contract for Medical Supplies to Afghanistan
Shukra Pharmaceuticals Limited has been awarded a ₹24.06 crore contract by HSCC (India) Limited to supply medicines and diagnostic kits to Afghanistan. The contract, backed by the Indian government, involves comprehensive services including delivery to the Technical Mission of India in Kabul. This development is expected to strengthen Shukra Pharma's international presence and demonstrate its capability to execute large-scale global healthcare supply projects.
13Aug 25
Shukra Pharmaceuticals Reports 112% Jump in Q1 Net Profit, Revenue Surges 70%
Shukra Pharmaceuticals Limited, a Gujarat-based pharmaceutical company, has reported impressive Q1 results for the period ended June 30. The company's net profit soared by 112% year-over-year to Rs 102.96 crore. Revenue from operations increased by 70% to Rs 539.11 crore, while total income reached Rs 650.08 crore. The company's strong performance is attributed to increased sales, operational efficiency, and a rise in other income. The Board of Directors approved these unaudited financial results on August 13.
25Jul 25
Shukra Pharmaceuticals Inks Service Agreement with PSU APITCO Limited for Healthcare Projects
Shukra Pharmaceuticals Limited has entered into a service agreement with APITCO Limited, a PSU under the Government of India, on July 18, 2025. The partnership aims to contribute to national-level healthcare initiatives, with Shukra acting as a business associate, healthcare project management consultant, and service & training provider. The collaboration will operate under defined Service Level Agreements for various healthcare government assignments. Neither company holds shareholding in the other, ensuring an independent partnership. This strategic move is expected to expand Shukra's presence in the public healthcare sector.
21Jul 25
Shukra Pharmaceuticals Expands Portfolio with 28 New Medical Device Distribution Partnerships
Shukra Pharmaceuticals Limited has obtained distribution rights for products from 28 leading surgical and medical instrument manufacturers. The company's expanded portfolio includes hematology analyzers, eye care equipment, orthopedic implants, ICU ventilators, and advanced wound dressing products. Notable partnerships include B. Braun, DJO Global, Integra, and Molnlycke Healthcare. This strategic move aims to capitalize on India's growing medical devices market, with both exclusive and non-exclusive distribution rights. The company expects significant revenue and business growth from this diversification.
10Jul 25
Shukra Pharmaceuticals Expands Footprint with Four New Branch Offices Across India
Shukra Pharmaceuticals announces plans to open new branch offices in Mumbai, Gurgaon (NCR), Bangalore, and Kolkata. This strategic expansion aims to strengthen the company's presence in major Indian cities, potentially enhancing market reach and operational capabilities. The move is expected to improve distribution networks, customer service, and access to local talent pools.
09Jul 25
Shukra Pharmaceuticals Expands Footprint with Four New Branches Across Major Indian Cities
Shukra Pharmaceuticals has announced the opening of four new branches in Mumbai, Gurgaon, Bangalore, and Kolkata. This expansion aims to strengthen the company's presence in key metropolitan areas across India, potentially enhancing market reach, improving distribution, and boosting brand visibility. The move comes amid growth in the Indian pharmaceutical industry and increased demand for healthcare products and services.
27Jun 25
Shukra Pharma Secures ₹115.9 Crore Order, Boosting Business Prospects
Shukra Pharmaceuticals has obtained a significant order worth ₹115.90 crore. While specific details about the order and client remain undisclosed, this development is expected to boost the company's revenue, strengthen its market position, and potentially lead to operational scaling. The order's magnitude suggests a positive impact on the company's financial outlook and may increase investor confidence.
Shukra Pharmaceuticals
40.97
+0.80
(+1.99%)
1 Year Returns:+503.39%
Industry Peers
Sun Pharmaceutical
1,691.40
(+0.33%)
Divis Laboratories
6,656.50
(-3.30%)
Cipla
1,505.70
(+0.28%)
Torrent Pharmaceuticals
3,580.00
(+0.75%)
Dr Reddys Laboratories
1,205.40
(+0.02%)
Zydus Life Science
944.10
(+0.79%)
Mankind Pharma
2,261.80
(-2.05%)
Lupin
1,971.80
(+0.83%)
Alkem Laboratories
5,668.50
(+0.44%)
Aurobindo Pharma
1,123.80
(-1.47%)